Evidence of EZH2 dependent and independent mechanisms of tazemetostat treatment emergent resistance in models of diffuse large B cell lymphoma

被引：0
|
作者：
Campbell, Carly T.
Jasper, Jeff S.
Daigle, Scott R.
Ribich, Scott A.
Keilhack, Heike
Smith, Jesse S.
Ho, Peter T.
Blakemore, Stephen J.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
312
引用
收藏
页数：3
相关论文
共 50 条
  • [21] EZH2 EXPRESSION DETERMINED BY IMMUNOHISTOCHEMISTRY DOES NOT CORRELATE WITH THE PRESENCE OF EZH2 MUTATIONS IN A SERIES OF DIFFUSE LARGE B-CELL LYMPHOMAS (DLBCL)
    Garcia, M.
    Fernandez-Rodriguez, C.
    Casado, B.
    Baro, M.
    Puiggros, A.
    Salido, M.
    Alamo, A.
    Gimeno, E.
    Sanchez-Gonzalez, B.
    Espinet, B.
    Serrano, S.
    Salar, A.
    Bellosillo, B.
    HAEMATOLOGICA, 2013, 98 : 350 - 350
  • [22] Analysis of c-MYC, EZH2, and Ki67 in Primary Diffuse Large B Cell Lymphoma of the Gastrointestinal Tract
    Vafaii, Pardis
    Nguyen, Johnny
    Zhang, Xiaohui
    Coppola, Domenico
    Zhang, Ling
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2016, 146
  • [23] Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma
    Park, Sungryul
    Jo, Seung-Hyun
    Kim, Jong-Hwan
    Kim, Seon-Young
    Ha, Jae Du
    Hwang, Jong Yeon
    Lee, Myeong Youl
    Kang, Jong Soon
    Han, Tae-Su
    Park, Sung Goo
    Kim, Sunhong
    Park, Byoung Chul
    Kim, Jeong-Hoon
    CANCERS, 2020, 12 (09) : 1 - 22
  • [24] Increased Expression of EZH2 Is Associated with Inferior Survival in Primary Central Nervous System Diffuse Large B-Cell Lymphoma
    Gibson, Briana
    Matnani, Rahul
    Ping, Zheng
    Chakravarthi, Balabhadrapatruni V. S. K.
    Yang, Yang
    Varambally, Sooryanarayana
    Peker, Denise
    BLOOD, 2016, 128 (22)
  • [25] Treatment of Diffuse Large B Cell Lymphoma
    Kwak, Jae-Yong
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2012, 27 (04): : 369 - 377
  • [26] EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
    Brach, Dorothy
    Johnston-Blackwell, Danielle
    Drew, Allison
    Lingaraj, Trupti
    Motwani, Vinny
    Warholic, Natalie M.
    Feldman, Igor
    Plescia, Christopher
    Smith, Jesse J.
    Copeland, Robert A.
    Keilhack, Heike
    Chan-Penebre, Elayne
    Knutson, Sarah K.
    Ribich, Scott A.
    Raimondi, Alejandra
    Thomenius, Michael J.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (11) : 2586 - 2597
  • [27] The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment
    Yuan, Hepei
    Nishikori, Momoko
    Otsuka, Yasuyuki
    Arima, Hiroshi
    Kitawaki, Toshio
    Takaori-Kondo, Akifumi
    CANCER SCIENCE, 2021, 112 (11) : 4604 - 4616
  • [28] TAZEMETOSTAT Histone-lysine N-methyltransferase EZH2 inhibitor Treatment of solid tumors Treatment of B-cell lymphomas
    Marques, F.
    DRUGS OF THE FUTURE, 2016, 41 (10) : 595 - 599
  • [29] Mechanism and Treatment of Rituximab Resistance in Diffuse Large B-cell Lymphoma
    Zou, Linqing
    Song, Guoqi
    Gu, Siyu
    Kong, Lingling
    Sun, Shiqi
    Yang, Li
    Cho, William C.
    CURRENT CANCER DRUG TARGETS, 2019, 19 (09) : 681 - 687
  • [30] Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma
    Pikman, Yana
    Conway, Amy Saur
    Robichaud, Amanda L.
    Kitara, Samuel
    Church, Alanna J.
    Kennedy, Alyssa L.
    Silverman, Lewis B.
    Billett, Amy L.
    Weinstock, David M.
    Harris, Marian H.
    Stegmaier, Kimberly
    BLOOD ADVANCES, 2020, 4 (07) : 1265 - 1269
12345